Abstract
Chronic pain interferes with daily functioning and is frequently accompanied by depression. Currently, traditional clinic treatments do not produce satisfactory analgesic effects and frequently result in various adverse effects. Pathogen recognition receptors (PRRs) serve as innate cellular sensors of danger signals, sense invading microorganisms, and initiate innate and adaptive immune responses. Among them, cGAS-STING alerts on the presence of both exogenous and endogenous DNA in the cytoplasm, and this pathway has been closely linked to multiple diseases, including auto-inflammation, virus infection, and cancer. An increasing numbers of evidence suggest that cGAS-STING pathway involves in the chronic pain process; however, its role remains controversial. In this narrative review, we summarize the recent findings on the involvement of the cGAS-STING pathway in chronic pain, as well as several possible mechanisms underlying its activation. As a new area of research, this review is unique in considering the cGAS-STING pathway in sensory neurons and glial cells as a part of a broader understanding of pain, including potential mechanisms of inflammation, immunity, apoptosis, and autophagy. It will provide new insight into the treatment of pain in the future.
Introduction
Chronic pain is classified as neuropathic and inflammatory pain that affects many patients worldwide. In contrast to short-lasting acute pain, chronic pain can be caused by various conditions. Once developed, it may seriously affect the patient's quality of life and cause numerous syndromes. Mechanisms of chronic pain are complex; peripheral nerve lesions or chemical mediators may evoke receptors (nociceptors) sensitive to noxious stimuli in nerve fibers. The spinal cord then processes somatosensory information, further contributing to central sensitization (Descalzi et al., 2015). Typical treatment measures for chronic pain currently include opioid analgesics, non-steroidal anti-inflammatory drugs, and surgical intervention; however, they all have limited long-term benefits and certain risks. For instance, long-term use of opioids in patients will increase the risk of addiction and produce opioid-induced hyperalgesia (Brush, 2012). Meanwhile, surgical intervention may induce postoperative disability, and the recurrence rates are high (Tarnanen et al., 2012). How to alleviate chronic pain and improve patients' prognosis remains a global health problem to be solved. Thus, novel therapeutic targets are urgent and worth developing.
Recently, special attention has been paid to emphasizing and critically discussing the cGAS-STING pathway, which is a dominant pathway that responds to cytosolic DNA in the context of tumor immunity, cellular senescence, and inflammatory diseases (Ablasser and Chen, 2019). Concerning the roles of the cGAS-STING pathway in chronic pain, it has been reported that activating the cGAS-STING may have various effects. Some studies indicated that STING releases proinflammatory cytokines, which may cause neuroinflammation to aggravate chronic pain (Wang et al., 2019; Tian et al., 2020; Sun et al., 2021). In contrast, another study showed that type 1 interferons over-activated by cGAS-STING pathway might exert an antinociceptive effect in sensory neurons (Donnelly et al., 2021). Today, cGAS-STING pathway in host immunity is more understood, and the therapeutic approaches targeting this pathway show promise for future clinical pain applications. Given the limitations of the current research, we review recent literature focusing on several chronic pain models such as low back pain, bone cancer pain, and spared nerve injury, demonstrating that cGAS-STING pathway is central to the progression and maintenance of chronic pain (Figure 1), but our understanding of its diverse functions on chronic pain still remains incomprehensible.
Figure 1
The diversity of cGAS-STING pathway activation in chronic pain and its related pathways.
Overview of cGAS-STING signaling
Innate immunity is the first line of defense against foreign substances and pathogens, and recognizing DNA is one of the most fundamental aspects of host defense. Pathogen recognition receptors (PRRs) serve as innate cellular sensors of danger signals, detect invading microorganisms, and initiate innate and adaptive immune responses (Thompson et al., 2011). PRRs comprised of toll-like receptors (TLRs), retinoic acid-inducible gene I-like receptors (RLRs), nucleotide oligomerization domain-like receptors (NLRs, also called NACHT, LRR, and PYD domain proteins), and cytosolic DNA sensors (Thompson et al., 2011). In 2008, several research teams discovered a new protein named “stimulator of interferon genes” (STING), which is the major type of innate immune receptor in the endoplasmic reticulum (ER) (Ishikawa and Barber, 2008). Bacteria-derived cyclic di-guanylate monophosphate (c-dGMP) or cyclic di-adenosine monophosphate (c-dAMP) were confirmed to be ligands for STING (Burdette et al., 2011).
First, cGAS is activated upon dsDNA recognition, undergoes an allosteric structural change, and subsequently catalyzes the synthesis of cyclic dinucleotide GMP-AMP (cGAMP) (Wan et al., 2020). Second, cGAMP interacts with and activates STING, which is a multi-structure transmembrane protein mainly located in the endoplasmic reticulum (ER). Subsequently, STING translocates from ER to ER-Golgi intermediate compartment (ERGIC) and afterward to the Golgi. Third, the c-terminal tail of the STING recruits TBK1 through a conserved PLPLRT/SD amino acid-binding motif and promotes the autophosphorylation of TBK1 in Golgi. After TBK1 phosphorylation, the complex of STING and TBK1 may further recruit IRF3 to phosphorylate it (Couillin and Riteau, 2021). IRF3 phosphorylation aimed to promote its dimerization, nuclear translocation, and target gene induction of type 1 interferons. Additionally, IRF3 activity is essential for inducing numerous target genes, including genes encoding inflammasome (such as NLRP3) and proinflammatory cytokines (Li et al., 2019). Another major signaling module in the STING pathway is that TBK1 may promote NF-κB activation by triggering nuclear translocation of NF-κB (Yum et al., 2021).
The activators of the cGAS-STING pathway in chronic pain
In vivo, host detection of pathogen-derived nucleic acids by pathogen recognition receptors (PRRs) is involved in context-dependent recognition of intrinsic dsDNA and extrinsic dsDNA (Thompson et al., 2011). Notably, emerging studies paid attention to PRRs as molecules involved in the pathogenesis of neuropathic pain (Kato et al., 2016). Therefore, it is reasonable to believe that the potential release of extrinsic and intrinsic dsDNA may activate the cGAS-STING pathway in chronic pain.
Activated by extrinsic DsDNA
Extrinsic dsDNA, from pathogens such as viruses, bacteria, and parasites, can be internalized into the cytosol in several ways to activate the cGAS-STING pathway (Diamond et al., 2018). The patrol nuclease degrades the dsDNA entering the cell in the lysosome or cytoplasm. In cells with abundant dsDNA or a lack of nuclease, internalized DNA may remain in the cytoplasm and be converted into cGAMP to activate STING (Ablasser et al., 2013). Currently, the evidence indicates that SARS-CoV-2, the etiologic agent of COVID-19, can damage and alter the nervous system, causing headaches and myalgia (Abboud et al., 2020). Another report has suggested that the pain may be related to the increase of type 1 interferons, which is the downstream of STING in young patients (Papa et al., 2021). Simultaneously, an animal experiment has also proved that viral infection induces pain by directly affecting nociceptors in dorsal root ganglion with type 1 interferons (Barragán-Iglesias et al., 2020). The above studies suggest that extrinsic dsDNA-like viruses and bacteria may cause pain via activating the cGAS-STING pathway.
The intrinsic self-dsDNA may activate cGAS-STING in chronic pain
Furthermore, extrinsic dsDNA and intrinsic dsDNA can activate cGAS-STING pathway and induce chronic pain. For example, self-dsDNA was increased and mediated the activation of cGAS-STING pathway in the spinal cord, contributing to the spared nerve injury (SNI)-induced neuropathic pain (Sun et al., 2021). The intrinsic self-dsDNA is composed of nDNA and mtDNA, which can be segregated inaccurately and released into the cytosol, triggering the STING pathway (Bhattacharya et al., 2017). Additionally, in the peripheral neuropathy pain model, DNA damage and the nuclear DNA released are associated with pain production (Canta et al., 2015), suggesting that STING may be activated in that pain model. Another intrinsic dsDNA was mtDNA, which is a component of mitochondria that belongs to the only non-nuclear genome. Compared with nDNA, mtDNA is more unstable and vulnerable to the effects of oxidative stress due to its proximity to mitochondrial reactive oxygen species (mtROS) and a lack of repair machinery. mtDNA stress may contribute to the cGAS-STING pathway activation and type 1 interferon responses in various pathological states, including infectious diseases, cancer, neurodegeneration, and other mitochondria-related illnesses (Zhou et al., 2021). Importantly, it has been established that mtDNA depletion inhibited the cGAS-STING pathway and nuclear translocation of p65 and IRF3 (Zhou et al., 2021).
Additionally, mitochondrial dysfunction contributes to the etiology of pain, as indicated by microscopic analysis performed on peripheral nerve sensory axons: abundant vacuolated and swollen mitochondria were observed in the rats treated with paclitaxel to induce pain (Canta et al., 2015; Dai et al., 2020). The increase of mtDNA is associated with pain-like behavior (Trecarichi et al., 2022). Additionally, it has evidenced that mtDNA released and activated the cGAS-STING pathway in low back pain model (Ning et al., 2020). Altogether, this evidence above suggests that mtDNA or nuclear DNA released may activate the cGAS-STING pathway in the process of chronic pain.
Other PRRs, such as TLRs, may be involved in the activation of cGAS-STING of chronic pain
Several lines of evidence have shown that Toll-like receptors (TLRs) signaling enables the cGAS-STING pathway to induce a strong type 1 interferon response during HIV-1 infection (Siddiqui and Yamashita, 2021). Additionally, TLR4 has been considered essential for activating the cGAS-STING pathway in macrophages stimulated by LPS (Ning et al., 2020), although current studies have suggested that after nerve injury, TLRs are involved in Wallerian degeneration and the generation of neuropathic pain (Thakur et al., 2017). Particularly, TLR3 promotes neuropathic pain by regulating autophagy in rats with L5 spinal nerve ligation model (Chen and Lu, 2017), and knockdown of TLR3 in bone malignancy pain model mice can impair pain thoroughly (Zhang et al., 2020). Furthermore, TLR3 has also been proven to trigger type 1 interferon responses via Toll/IL-1 receptor domain containing adaptor inducing IFN-β (TRIF) signaling to regulate pain and itch (Szöllosi et al., 2019). It is suggested that TLRs may be involved in activating the cGAS-STING pathway in chronic pain, although it remains to be examined.
The main downstream signaling pathways of cGAS-STING in chronic pain
Type 1 interferons
The cGAS-STING pathway, which controls immunity to cytosolic DNA, is a critical driver of aberrant type 1 interferon responses (Domizio et al., 2022). Furthermore, the latest research on COVID-19 has revealed that type 1 interferon response, which is activated by cGAS-STING pathway, induces microangiopathic changes and produces neuropathic pain in young patients (Papa et al., 2021). Simultaneously, according to a study of hepatitis C virus patients, IFN-α therapy causes significant somatic pain and promotes major depressive disorder as early as the second week of treatment (Lin et al., 2020), although early reports have demonstrated that IFN-α and IFN-β, two major family members of type 1 interferons, exert an antinociceptive action (Menzies et al., 1992). In addition, STING regulates the type 1 interferon signaling in dorsal root ganglion sensory neurons, which has been disclosed to control nociception in bone cancer pain models (Donnelly et al., 2021). Consistently, in chronic constriction injury-induced neuropathic pain, protein tyrosine phosphatase receptor type D (PTPRD) activates STING-type 1 interferon pathway in dorsal root ganglion and displays an analgesic effect (Sun et al., 2022). In the light of this, researchers have reviewed that IFN-α and IFN-β may rapidly suppress neuronal activity and synaptic transmission to potent analgesia via nongenomic regulation (Tan et al., 2021), while the discrepancy in antinociceptive against pronociceptive effects of type 1 interferons may ascribe to various conditions, and the exact role of STING/type 1 interferons in chronic pain requires further investigation.
NLRP3
STING predominantly inhabits the endoplasmic reticulum to regulate innate immune signaling processes and recruits NLRP3 to the ER to promote the inflammasome formation in the HSV-1 infection (Wang et al., 2020). Lipopolysaccharide (LPS) activates STING and afterward upregulates NLRP3 expression in acute lung injury (Ning et al., 2020). Simultaneously, an increasing body of evidence verified that NLRP3 inflammasome controls the processing of proinflammatory cytokine interleukin 1β (IL-1β) and is implicated in chronic pain (Pan et al., 2018; Chen et al., 2021). In another study of lower back pain, NLRP3 activation in nucleus pulposus cells was associated with cGAS and STING and participated in chronic pain (Tian et al., 2020). The inhibitor of NLRP3 inflammasome can effectively modify nitroglycerin-induced mechanical hyperalgesia (He et al., 2019). Therefore, NLRP3 has become an emerging therapeutic target for chronic pain, and it shows promise that STING may regulate NLRP3 to participate in chronic pain.
NF-κB
Nuclear factor-kappa B (NF-κB) is an important nuclear transcription factor in almost all cell types and participates in numerous biological processes, including inflammation, cell differentiation, immunity, cell growth and apoptosis, and tumorigenesis (Ghosh and Dass, 2016). STING activation can trigger nuclear factor κB (NF-κB) signaling to mediate immune defense against tumors and viral infections (Yum et al., 2021). Simultaneously, STING antagonist H-151 has been shown that suppresses STING/NF-κB-mediated inflammation to ameliorate psoriasis (Pan et al., 2021). Notably, the latest research in neuropathic pain has indicated that STING may activate the NF-κB and release the proinflammatory cytokines IL-6 in the spinal cord to aggravate chronic pain. However, injecting STING antagonist C-176 can provide an analgesic effect and reverse the increased expression of NF-κB (Sun et al., 2021). Additionally, NF-κB is a transcription factor for various cytokines, including CX3CL1, IL-1β, IL-6, and TNF-α, to induce peripheral and central sensitization in chronic pain (Sun et al., 2012; Liu et al., 2018; Xiang et al., 2019; Li Y. et al., 2020; Xu et al., 2021). Undoubtedly, NF-κB activation may contribute to chronic pain; therefore, as an important mediator of NF-κB, STING is supposed to play a significant role in chronic pain.
The potential mechanism of the cGAS-STING pathway in chronic pain
The extrinsic dsDNA (virus and bacteria), intrinsic dsDNA (nDNA and mtDNA), and other pathogen recognition receptors (PRRs) such as Toll-like receptors (TLRs) may contribute to chronic pain by activating the cGAS-STING pathway. Meanwhile, the downstream proteins of the cGAS-STING pathway, such as type 1 interferons, NLRP3, and NF-κB, have been established that participate in chronic pain. Furthermore, cluster analysis displayed that cGAS-STING activation could affect inflammation, immunity, apoptosis, autophagy, and other signaling pathways (Wu et al., 2020); these cellular processes may involve chronic pain. Based on the preceding evidence, we hypothesized that the cGAS-STING pathway might significantly affect chronic pain.
cGAS-STING may induce inflammation to contribute to chronic pain
Evidence accumulates that STING pathway is involved in inflammation (Chin, 2019); for instance, STING-mediated type 1 interferons regulates the elevation of proinflammatory cytokine profile with increased TNF-α, IL-6, and IL-1β in microglia of traumatic brain injury (Abdullah et al., 2018). Moreover, these studies have revealed that the cGAS-STING pathway was activated, and the inflammatory cytokines IL-6 and CXCL10 were released in mitochondrial dysfunction (Zhou et al., 2021). Additionally, in cerebral ischemic stroke, cGAS knockdown promotes microglial M2 polarization to alleviate inflammation (Jiang et al., 2021). Emerging evidence suggested that inflammation plays an essential role in chronic pain (Ji et al., 2016, 2018): The upregulation of inflammatory mediators (TNF-α, IL-6, and IL-1β) in the spinal cord has been evidenced that might be involved in the process of bone cancer pain. Inhibition of endoplasmic reticulum stress may decrease the inflammatory mediators and show an antinociception effect (Wei et al., 2016; Mao et al., 2020). Particularly, in inflammatory pain, magnetic resonance imaging (MRI) and histopathology have demonstrated that inflammation caused by cGAS, STING, and NLRP3 is associated with intervertebral disc degeneration in low back pain (Zhang et al., 2022). Moreover, STING can also participate in the inflammatory reaction process of neuropathic pain. In spinal cord injury mice, STING knockout may alleviate inflammatory response (Wang et al., 2019); in spared nerve injury rats, STING inhibitor C-176 administration provides an antinociceptive effect that is reversed by injecting recombinant IL-6 (Sun et al., 2021), which indicates that STING is an essential downstream factor for chronic pain by regulating IL-6 expression. Accordingly, it would not surprise that activation of the cGAS-STING pathway may induce inflammation to mediate inflammatory and neuropathic pain.
cGAS-STING may mediate immunity to participate in chronic pain
The cGAS-STING pathway has a significant role in the immune, and emerging studies provide solid evidence that cGAS-STING is mainly attributed to antigen-presenting cell (APC)-mediated activation of CD8+ T cells (Flood et al., 2019) and spontaneous CD8+ T cell priming against tumors was defective in mice lacking STING (Woo et al., 2014). Meanwhile, cGAS-STING-mediated DNA sensing has been reported that maintains CD8+ T cell stemness and promotes anti-tumor T cell therapy (Li W. et al., 2020). Although the clinical research disclosed that STING agonist ADU-S100 might induce CD8+ T cell immune response at a low dose, when administered at a high dose, the CD8+ T cell death, and compromised anti-tumor immunity (Sivick et al., 2018), it is no doubt that STING mediates CD8+ T cells.
A variety of inflammatory pain processes are believed to be mediated by T cells, including rheumatoid arthritis, intestinal inflammation, etc. (Basso et al., 2015; Swain et al., 2022). Recent studies have found that T cells are also involved in neuropathic pain: CD8+ T cells and endogenous IL-10 are required to resolve chemotherapy-induced neuropathic pain (Krukowski et al., 2016); educating CD8+ T cells can prevent and resolve chemotherapy-induced peripheral neuropathy in mice (Laumet et al., 2019; Singh et al., 2022). Intriguingly, in the bone cancer pain model which may involve both inflammatory pain and neuropathic pain, systemic administration of STING activator DMXAA attenuated the measures of spontaneous and ongoing pain; the analgesic effect may attribute to the increasing proportion of CD8+ T cells in the bone marrow tumor microenvironment (Donnelly et al., 2021). Therefore, these findings suggest that the cGAS-STING pathway may involve chronic pain by mediating the immunity of CD8+ T cells.
cGAS-STING may induce autophagy to contribute to chronic pain
Autophagy is a lysosomal degradation pathway that maintains tissue homeostasis by recycling damaged and aged cellular components, which plays a significant role in developing the nervous system, neuronal function, and survival (Liu X. et al., 2019). Emerging studies showed that innate immunity-related proteins control the progress of autophagy (Wild et al., 2011). Extracellular M. tuberculosis DNA induces autophagy by activating the cGAS-STING pathway, suggesting a link between STING and autophagy (Watson et al., 2012). Additionally, injecting the activator of IRF3, the downstream protein of the cGAS-STING pathway, can inhibit the fusion of the autophagosome with the lysosome to reduce autophagy flux (67), indicating that the activation of the STING pathway may impair the autophagy. In neuropathic pain, autophagy flux is impaired and mainly exists in astrocytes during the maintenance of the study by Li et al. (2021) and Liao et al. (2022); no matter the stage of neuropathic pain induction or maintenance, upregulation of autophagy can suppresses pain behavior (Li et al., 2021). Researchers suggest that upregulated autophagic activities may facilitate myelin clearance, promote nerve regeneration, and reduce pain. Furthermore, the cGAS-STING pathway has been reported to directly interact with microtubule-associated protein light chain 3 (LC3) and subsequent autophagy to regulate the innate immune responses (Liu D. et al., 2019). The expression of LC3 is upregulated in GABAergic interneurons of rat spinal dorsal horn after SNL, suggesting that autophagic disruption following SNL might be involved in the induction and maintenance of neuropathic pain (Liu X. et al., 2019). Intrathecal injection of autophagy activator exerts an analgesic effect on neuropathic pain by activating LC3 in astrocytes (Yuan and Fei, 2021). It can be suggested that STING may interact with LC3 to aggravate chronic pain further. The role of autophagy in inflammatory pain has been studied relatively less, while a study by Liu found that CFA-induced inflammatory pain can be alleviated by restoring autophagic flux in the spinal cord (Liu et al., 2022). Autophagy may mediate both inflammatory and neuropathic pain, although there is no solid evidence to confirm this hypothesis, it is still appropriate to predict that STING may mediate autophagy flux and contribute to chronic pain.
cGAS-STING may induce apoptosis to contribute to chronic pain
Apoptosis is a form of programmed cell death and shrinkage when cells encounter stress or damage (Liao et al., 2022). There is evidence for this occurring that STING-dependent apoptosis directly through the interaction of IRF3 and BCL2-associated x, apoptosis regulator (Bax) (Sze et al., 2013), and in microglia and other immune cells, HSV-1 at a high viral load can trigger cGAS/STING-dependent apoptosis (Reinert et al., 2021). Additionally, STING-IRF3 contributes to lipopolysaccharide-induced cardiac apoptosis via activating NLRP3 (Li et al., 2019). Consequently, cGAS-STING pathway is essential for apoptosis regulation. Furthermore, apoptotic activity in the injured nerve, dorsal root ganglia, and spinal cord has changed during neuropathic pain formation (Liao et al., 2022). The number of cleaved caspase-3 in the spinal cord increased on days 8 and 14 after nerve injury (Fu et al., 2017). Meanwhile, increased spinal cell apoptosis may probably induce inflammatory pain (Baniasadi et al., 2020). Although there is no clear evidence demonstrating that inhibiting apoptotic activities could attenuate pain behavior, daily hyperbaric oxygen therapy has been proved to suppress pain behavior and reduce apoptotic activities of GABAergic neurons in the spinal dorsal horn of rats (Fu et al., 2017). The apoptosis level was increased in osteoarthritic, which develops slowly and worsens over time, accompanied by chronic pain (Aigner et al., 2001); recently, it has been evidenced that STING might induce apoptosis and senescence in chondrocytes via NF-κB pathway in osteoarthritic mice; STING knockdown may reduce the level of chondrocyte apoptosis and ameliorate the symptom (Guo et al., 2021). Simultaneously, epigallocatechin gallate also has been found that reduces the apoptotic rate via inhibiting the cGAS-STING pathway activation in nucleus pulposus cells of low back pain models (Tian et al., 2020). The process of apoptosis may contribute to the pathology of inflammatory or neuropathic pain. In view of cGAS-STING that can promote apoptosis in various diseases, it is proposed that cGAS-STING may induce apoptosis and promote chronic pain.
Concluding remarks and future perspectives
The cGAS-STING axis is initially recognized as the an essential mechanism for the host to defeat bacteria and virus invasions (Ding et al., 2020), as the crucial role in the neuro-immune, activation of immunostimulatory pathways is required for normal functioning, but the persistent engagement of these responses can prove detrimental.
It was found in the recent studies that the cGAS-STING may be an important mediator of chronic pain, and this review summarized and discussed the potential relationship. First, pathogens and damaged cells will release exogenous and endogenous DNA, which may activate the cGAS-STING pathway and then contribute to chronic pain. Additionally, TLRs were activated in chronic pain, which may be in concert with the cGAS-STING pathway. As such, it is unsurprising that the cGAS-STING pathway may be activated in chronic pain; however, the different types and mechanisms of DNA and TLRs should be further explored. Moreover, the activated STING further exerted its effect by promoting the expressions of type 1 interferons, NF-κB, and NLRP3. Intriguingly, the downstream has been shown to play a significant role in chronic pain. It can be conceived that the cGAS-STING pathway may mediate chronic pain by activating these downstream; however, more mechanisms are required for further research. Besides, STING may influence inflammation, immunity (such as CD8+ T cells), autophagy, and apoptosis, which has been proved to be the essential cause of chronic pain. Particularly, these cellular processes may influence each other in chronic pain; for example, LC3-associated phagocytosis can assist remove apoptotic cells by macrophages and inhibit proinflammatory processes (Eid and Ito, 2022). The relevance of these branches of cGAS/STING pathway for their potential role in chronic pain is currently not well-understood. Further research may be required to provide a more comprehensive picture of STING in chronic pain and pain-related cellular signals.
What role cGAS-STING plays in chronic pain is still controversial. Agonists and inhibitors targeting cGAS-STING have been developed with potentials for the treatment of auto-inflammation, virus infection, and cancers (Ding et al., 2020). In chronic-refractory pain, STING-related adjuvant therapy appears to have translational potential, and the latest research has reported that a small molecule drug 7-BIA could alleviate neuropathic pain by upregulating STING and IFN-α in the DRG (Sun et al., 2022). There is a possibility of developing new drugs that target the STING signal pathway to treat refractory cancer-induced bone pain or neuropathic pain in patients to avoid systemic effects.
STING enhances the production and secretion of type 1 interferons (IFN-α and IFN-ß). As we know, IFN-α and IFN-ß have already been successfully used for adjuvant therapy in malignancy, infection, and autoimmune disease. As well as trials of IFN-α, STING agonists more recently used for adjuvant anti-malignancy treatment were also tested (Lv et al., 2020; Verdegaal et al., 2020; Meric-Bernstam et al., 2022). It is therefore possible to determine whether low-dose IFN-α and STING agonists reduced or induced pain by examining existing datasets and patients previously treated with this drug.
Additionally, STING's effect on nociceptors, which affect immune cells (Donnelly et al., 2021), might be an interesting target in basic science. If immune-mediated attenuation of STING's analgesic function occurs, then the analgesic effects of STING could be further enhanced by blocking (currently unknown) immune-mediated pro-analgesic effects. What is the mechanism by which immune cells modulate STING's analgesic effects? How the new STING analgesic signaling plays out in young/old subjects, and whether male/female sex differences exist? There are still questions to be answered.
Funding
This work was supported by the National Natural Science Foundation of China (grant No. 82071233), Shanghai Sailing Program (grant No. 21YF1442900), and Nurture projects for basic research of Shanghai Chest Hospital (grant Nos. 2019YNJCM08, 2020YNJCQ13).
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
JW, XL, and XZ searched the literature and participated in manuscript preparation. WW, JW, and XY made the critical revision of the manuscript. All authors have read and approved the final manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbboudH.AbboudF. Z.KharbouchH.ArkhaY.El AbbadiN.El OuahabiA. (2020). COVID-19 and SARS-CoV-2 infection: pathophysiology and clinical effects on the nervous system. World Neurosurg.140, 49–53. 10.1016/j.wneu.2020.05.193
2
AbdullahA.ZhangM.FrugierT.BedouiS.TaylorJ. M.CrackP. J. (2018). STING-mediated type-I interferons contribute to the neuroinflammatory process and detrimental effects following traumatic brain injury. J. Neuroinflamm.15, 323. 10.1186/s12974-018-1354-7
3
AblasserA.Schmid-BurgkJ. L.HemmerlingI.HorvathG. L.SchmidtT.LatzE.et al. (2013). Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature503, 530–534. 10.1038/nature12640
4
AblasserA.ChenZ. J. (2019). cGAS in action: expanding roles in immunity and inflammation. Science 363, eaat8657. 10.1126/science.aat8657
5
AignerT.HemmelM.NeureiterD.GebhardP. M.ZeilerG.KirchnerT.et al. (2001). Apoptotic cell death is not a widespread phenomenon in normal aging and osteoarthritis human articular knee cartilage: a study of proliferation, programmed cell death (apoptosis), and viability of chondrocytes in normal and osteoarthritic human knee cartilage. Arthrit. Rheum.44, 1304–1312. 10.1002/1529-0131(200106)44:6<1304::AID-ART222>3.0.CO
6
BaniasadiM.ManahejiH.MaghsoudiN.DanyaliS.ZakeriZ.MaghsoudiA.et al. (2020). Microglial-induced apoptosis is potentially responsible for hyperalgesia variations during CFA-induced inflammation. Inflammopharmacology28, 475–485. 10.1007/s10787-019-00623-3
7
Barragán-IglesiasP.Franco-EnzástigaÚ.JeevakumarV.ShiersS.WangzhouA.Granados-SotoV.et al. (2020). Type I interferons act directly on nociceptors to produce pain sensitization: implications for viral infection-induced pain. J. Neurosci.40, 3517–3532. 10.1523/JNEUROSCI.3055-19.2020
8
BassoL.BourreilleA.DietrichG. (2015). Intestinal inflammation and pain management. Curr. Opin. Pharmacol.25, 50–55. 10.1016/j.coph.2015.11.004
9
BhattacharyaS.SrinivasanK.AbdisalaamS.SuF.RajP.DozmorovI.et al. (2017). RAD51 interconnects between DNA replication, DNA repair and immunity. Nucleic Acids Res.45, 4590–4605. 10.1093/nar/gkx126
10
BrushD. E. (2012). Complications of long-term opioid therapy for management of chronic pain: the paradox of opioid-induced hyperalgesia. J. Med. Toxicol.8, 387–392. 10.1007/s13181-012-0260-0
11
BurdetteD. L.MonroeK. M.Sotelo-TrohaK.IwigJ. S.EckertB.HyodoM.et al. (2011). STING is a direct innate immune sensor of cyclic di-GMP. Nature478, 515–518. 10.1038/nature10429
12
CantaA.PozziE.CarozziV. A. (2015). Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN). Toxics3, 198–223. 10.3390/toxics3020198
13
ChenR.YinC.FangJ.LiuB. (2021). The NLRP3 inflammasome: an emerging therapeutic target for chronic pain. J. Neuroinflamm.18, 84. 10.1186/s12974-021-02131-0
14
ChenW.LuZ. (2017). Upregulated TLR3 promotes neuropathic pain by regulating autophagy in rat with L5 spinal nerve ligation model. Neurochem. Res.42, 634–643. 10.1007/s11064-016-2119-2
15
ChinA. C. (2019). Neuroinflammation and the cGAS-STING pathway. J. Neurophysiol.121, 1087–1091. 10.1152/jn.00848.2018
16
CouillinI.RiteauN. (2021). STING signaling and sterile inflammation. Front. Immunol.12, 753789. 10.3389/fimmu.2021.753789
17
DaiC. Q.GuoY.ChuX. Y. (2020). Neuropathic pain: the dysfunction of Drp1, mitochondria, and ROS homeostasis. Neurotox. Res.38, 553–563. 10.1007/s12640-020-00257-2
18
DescalziG.IkegamiD.UshijimaT.NestlerE. J.ZachariouV.NaritaM. (2015). Epigenetic mechanisms of chronic pain. Trends Neurosci.38, 237–246. 10.1016/j.tins.2015.02.001
19
DiamondJ. M.Vanpouille-BoxC.SpadaS.RudqvistN. P.ChapmanJ. R.UeberheideB. M.et al. (2018). Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs. Cancer Immunol. Res.6, 910–920. 10.1158/2326-6066.CIR-17-0581
20
DingC.SongZ.ShenA.ChenT.ZhangA. (2020). Small molecules targeting the innate immune cGAS–STING–TBK1 signaling pathway. Acta Pharm. Sin. B10, 2272–2298. 10.1016/j.apsb.2020.03.001
21
DomizioJ. D.GulenM. F.SaidouneF.ThackerV. V.YatimA.SharmaK.et al. (2022). The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature603, 145–151. 10.1038/s41586-022-04421-w
22
DonnellyC. R.JiangC.AndriessenA. S.WangK.WangZ.DingH.et al. (2021). STING controls nociception via type I interferon signalling in sensory neurons. Nature591, 275–280. 10.1038/s41586-020-03151-1
23
EidN.ItoY. (2022). Oxoglaucine alleviates osteoarthritis by activation of autophagy via blockade of Ca(2+) influx and TRPV5/calmodulin/CAMK-II pathway. Br. J. Pharmacol.179, 1282–1283. 10.1111/bph.15706
24
FloodB. A.HiggsE. F.LiS.LukeJ. J.GajewskiT. F. (2019). STING pathway agonism as a cancer therapeutic. Immunol. Rev.290, 24–38. 10.1111/imr.12765
25
FuH.LiF.ThomasS.YangZ. (2017). Hyperbaric oxygenation alleviates chronic constriction injury (CCI)-induced neuropathic pain and inhibits GABAergic neuron apoptosis in the spinal cord. Scand J. Pain17, 330–338. 10.1016/j.sjpain.2017.08.014
26
GhoshS.DassJ. F. P. (2016). Study of pathway cross-talk interactions with NF-κB leading to its activation via ubiquitination or phosphorylation: a brief review. Gene584, 97–109. 10.1016/j.gene.2016.03.008
27
GuoQ.ChenX.ChenJ.ZhengG.XieC.WuH.et al. (2021). STING promotes senescence, apoptosis, and extracellular matrix degradation in osteoarthritis via the NF-κB signaling pathway. Cell Death Dis.12, 13. 10.1038/s41419-020-03341-9
28
HeW.LongT.PanQ.ZhangS.ZhangY.ZhangD.et al. (2019). Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model. J. Neuroinflamm.16, 78. 10.1186/s12974-019-1459-7
29
IshikawaH.BarberG. N. (2008). STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature455, 674–678. 10.1038/nature07317
30
JiR. R.ChamessianA.ZhangY. Q. (2016). Pain regulation by non-neuronal cells and inflammation. Science354, 572–577. 10.1126/science.aaf8924
31
JiR. R.NackleyA.HuhY.TerrandoN.MaixnerW. (2018). Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology129, 23. 10.1097/ALN.0000000000002130
32
JiangG. L.YangX. L.ZhouH. J.LongJ.LiuB.ZhangL. M.et al. (2021). cGAS knockdown promotes microglial M2 polarization to alleviate neuroinflammation by inhibiting cGAS-STING signaling pathway in cerebral ischemic stroke. Brain Res. Bull.171, 183–195. 10.1016/j.brainresbull.2021.03.010
33
KatoJ.AgalaveN. M.SvenssonC. I. (2016). Pattern recognition receptors in chronic pain: mechanisms and therapeutic implications. Eur. J. Pharmacol.788, 261–273. 10.1016/j.ejphar.2016.06.039
34
KrukowskiK.EijkelkampN.LaumetG.HackC. E.LiY.DoughertyP. M.et al. (2016). CD8+ T cells and endogenous IL-10 are required for resolution of chemotherapy-induced neuropathic pain. J. Neurosci.36, 11074–11083. 10.1523/JNEUROSCI.3708-15.2016
35
LaumetG.EdralinJ. D.DantzerR.HeijnenC. J.KavelaarsA. (2019). Cisplatin educates CD8+ T cells to prevent and resolve chemotherapy-induced peripheral neuropathy in mice. Pain160, 1459–1468. 10.1097/j.pain.0000000000001512
36
LiJ.TianM.HuaT.WangH.YangM.LiW.et al. (2021). Combination of autophagy and NFE2L2/NRF2 activation as a treatment approach for neuropathic pain. Autophagy17, 4062–4082. 10.1080/15548627.2021.1900498
37
LiN.ZhouH.WuH.WuQ.DuanM.DengW.et al. (2019). STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol.24, 101215. 10.1016/j.redox.2019.101215
38
LiW.LuL.LuJ.WangX.YangC.JinJ.et al. (2020). cGAS-STING-mediated DNA sensing maintains CD8(+) T cell stemness and promotes antitumor T cell therapy. Sci. Transl. Med. 12, eaay9013. 10.1126/scitranslmed.aay9013
39
LiY.YangY.GuoJ.GuoX.FengZ.ZhaoX. (2020). Spinal NF-kB upregulation contributes to hyperalgesia in a rat model of advanced osteoarthritis. Mol. Pain16, 1744806920905691. 10.1177/1744806920905691
40
LiaoM. F.LuK. T.HsuJ. L.LeeC. H.ChengM. Y.RoL. S. (2022). The role of autophagy and apoptosis in neuropathic pain formation. Int. J. Mol. Sci.23, 2685. 10.3390/ijms23052685
41
LinC. Y.GuuT. W.LaiH. C.PengC. Y.ChiangJ. Y.ChenH. T.et al. (2020). Somatic pain associated with initiation of interferon-alpha (IFN-α) plus ribavirin (RBV) therapy in chronic HCV patients: a prospective study. Brain Behav. Immun. Health2, 100035. 10.1016/j.bbih.2019.100035
42
LiuC.ZhangF.LiuH.WeiF. (2018). NF-kB mediated CX3CL1 activation in the dorsal root ganglion contributes to the maintenance of neuropathic pain induced in adult male Sprague Dawley rats1. Acta Cir. Bras.33, 619–628. 10.1590/s0102-865020180070000007
43
LiuC.ZhengX.LiuL.HuY.ZhuQ.ZhangJ.et al. (2022). Caloric restriction alleviates CFA-induced inflammatory pain via elevating β-hydroxybutyric acid expression and restoring autophagic flux in the spinal cord. Front. Neurosci.16, 828278. 10.3389/fnins.2022.828278
44
LiuD.WuH.WangC.LiY.TianH.SirajS.et al. (2019). STING directly activates autophagy to tune the innate immune response. Cell Death Differ.26, 1735–1749. 10.1038/s41418-018-0251-z
45
LiuX.ZhuM.JuY.LiA.SunX. (2019). Autophagy dysfunction in neuropathic pain. Neuropeptides75, 41–48. 10.1016/j.npep.2019.03.005
46
LvM.ChenM.ZhangR.ZhangW.WangC.ZhangY.et al. (2020). Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res.30, 966–979. 10.1038/s41422-020-00395-4
47
MaoY.WangC.TianX.HuangY.ZhangY.WuH.et al. (2020). Endoplasmic reticulum stress contributes to nociception via neuroinflammation in a murine bone cancer pain model. Anesthesiology132, 357–372. 10.1097/ALN.0000000000003078
48
MenziesR. A.PatelR.HallN. R.O'GradyM. P.RierS. E. (1992). Human recombinant interferon alpha inhibits naloxone binding to rat brain membranes. Life Sci. 50, Pl227–232. 10.1016/0024-3205(92)90555-4
49
Meric-BernstamF.SweisR. F.HodiF. S.MessersmithW. A.AndtbackaR. H. I.InghamM.et al. (2022). Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas. Clin. Cancer Res.28, 677–688. 10.1158/1078-0432.CCR-21-1963
50
NingL.WeiW.WenyangJ.RuiX.QingG. (2020). Cytosolic DNA-STING-NLRP3 axis is involved in murine acute lung injury induced by lipopolysaccharide. Clin. Transl. Med.10, e228. 10.1002/ctm2.228
51
PanY.YouY.SunL.SuiQ.LiuL.YuanH.et al. (2021). The STING antagonist H-151 ameliorates psoriasis via suppression of STING/NF-κB-mediated inflammation. Br. J. Pharmacol.178, 4907–4922. 10.1111/bph.15673
52
PanZ.ShanQ.GuP.WangX. M.TaiL. W.SunM.et al. (2018). miRNA-23a/CXCR4 regulates neuropathic pain via directly targeting TXNIP/NLRP3 inflammasome axis. J. Neuroinflamm.15, 29. 10.1186/s12974-018-1073-0
53
PapaA.SalzanoA. M.Di DatoM. T.Lo BiancoG.TedescoM.SalzanoA.et al. (2021). COVID-19 related acro-ischemic neuropathic-like painful lesions in pediatric patients: a case series. Anesth. Pain Med.11, e113760. 10.5812/aapm.113760
54
ReinertL. S.RashidiA. S.TranD. N.Katzilieris-PetrasG.HvidtA. K.GohrM.et al. (2021). Brain immune cells undergo cGAS/STING-dependent apoptosis during herpes simplex virus type 1 infection to limit type I IFN production. J. Clin. Invest.131, e136824. 10.1172/JCI136824
55
SiddiquiM. A.YamashitaM. (2021). Toll-like receptor (TLR) signaling enables cyclic GMP-AMP synthase (cGAS) sensing of HIV-1 infection in macrophages. MBio12, e0281721. 10.1128/mBio.02817-21
56
SinghS. K.KrukowskiK.LaumetG. O.WeisD.AlexanderJ. F.HeijnenC. J.et al. (2022). CD8+ T cell-derived IL-13 increases macrophage IL-10 to resolve neuropathic pain. JCI Insight7, e154194. 10.1172/jci.insight.154194
57
SivickK. E.DesbienA. L.GlickmanL. H.ReinerG. L.CorralesL.SurhN. H.et al. (2018). Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity. Cell Rep.25, 3074–3085.e3075. 10.1016/j.celrep.2018.11.047
58
SunC.WuG.ZhangZ.CaoR.CuiS. (2022). Protein tyrosine phosphatase receptor type D regulates neuropathic pain after nerve injury via the STING-IFN-I pathway. Front. Mol. Neurosci.15, 859166. 10.3389/fnmol.2022.859166
59
SunJ.ZhouY. Q.XuB. Y.LiJ. Y.ZhangL. Q.LiD. Y.et al. (2021). STING/NF-κB/IL-6-mediated inflammation in microglia contributes to spared nerve injury (SNI)-induced pain initiation. J. Neuroimmune Pharmacol. 10.1007/s11481-021-10031-6
60
SunT.LuoJ.JiaM.LiH.LiK.FuZ. (2012). Small interfering RNA-mediated knockdown of NF-κBp65 attenuates neuropathic pain following peripheral nerve injury in rats. Eur. J. Pharmacol.682, 79–85. 10.1016/j.ejphar.2012.02.017
61
SwainN.TripathyA.PadhanP.RaghavS. K.GuptaB. (2022). Toll-like receptor-7 activation in CD8+ T cells modulates inflammatory mediators in patients with rheumatoid arthritis. Rheumatol. Int.42, 1235–1245. 10.1007/s00296-021-05050-8
62
SzeA.BelgnaouiS. M.OlagnierD.LinR.HiscottJ.van GrevenyngheJ. (2013). Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe14, 422–434. 10.1016/j.chom.2013.09.009
63
SzöllosiA. G.McDonaldI.SzabóI. L.MengJ.van den BogaardE.SteinhoffM. (2019). TLR3 in chronic human itch: a keratinocyte-associated mechanism of peripheral itch sensitization. J. Invest. Dermatol.139, 2393–2396.e2396. 10.1016/j.jid.2019.04.018
64
TanP. H.JiJ.YehC. C.JiR. R. (2021). Interferons in pain and infections: emerging roles in neuro-immune and neuro-glial interactions. Front. Immunol.12, 783725. 10.3389/fimmu.2021.783725
65
TarnanenS.NevaM. H.DekkerJ.HäkkinenK.VihtonenK.PekkanenL.et al. (2012). Randomized controlled trial of postoperative exercise rehabilitation program after lumbar spine fusion: study protocol. BMC Musculoskelet. Disord.13, 123. 10.1186/1471-2474-13-123
66
ThakurK. K.SainiJ.MahajanK.SinghD.JayswalD. P.MishraS.et al. (2017). Therapeutic implications of toll-like receptors in peripheral neuropathic pain. Pharmacol. Res.115, 224–232. 10.1016/j.phrs.2016.11.019
67
ThompsonM. R.KaminskiJ. J.Kurt-JonesE. A.FitzgeraldK. A. (2011). Pattern recognition receptors and the innate immune response to viral infection. Viruses3, 920–940. 10.3390/v3060920
68
TianY.BaoZ.JiY.MeiX.YangH. (2020). Epigallocatechin-3-gallate protects H(2)O(2)-induced nucleus pulposus cell apoptosis and inflammation by inhibiting cGAS/Sting/NLRP3 activation. Drug Des. Devel. Ther.14, 2113–2122. 10.2147/DDDT.S251623
69
TrecarichiA.DuggettN. A.GranatL.LoS.MalikA. N.Zuliani-ÁlvarezL.et al. (2022). Preclinical evidence for mitochondrial DNA as a potential blood biomarker for chemotherapy-induced peripheral neuropathy. PLoS ONE17, e0262544. 10.1371/journal.pone.0262544
70
VerdegaalE.van der KooijM. K.VisserM.van der MinneC.de BruinL.MeijP.et al. (2020). Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study. J. Immunother. Cancer8, e000166. 10.1136/jitc-2019-000166
71
WanD.JiangW.HaoJ. (2020). Research advances in how the cGAS-STING pathway controls the cellular inflammatory response. Front. Immunol.11, 615. 10.3389/fimmu.2020.00615
72
WangW.HuD.WuC.FengY.LiA.LiuW.et al. (2020). STING promotes NLRP3 localization in ER and facilitates NLRP3 deubiquitination to activate the inflammasome upon HSV-1 infection. PLoS Pathog.16, e1008335. 10.1371/journal.ppat.1008335
73
WangY. Y.ShenD.ZhaoL. J.ZengN.HuT. H. (2019). Sting is a critical regulator of spinal cord injury by regulating microglial inflammation via interacting with TBK1 in mice. Biochem. Biophys. Res. Commun.517, 741–748. 10.1016/j.bbrc.2019.07.125
74
WatsonR. O.ManzanilloP. S.CoxJ. S. (2012). Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell150, 803–815. 10.1016/j.cell.2012.06.040
75
WeiT.GuoT.-Z.LiW.-W.KingeryW. S.ClarkJ. D. (2016). Acute versus chronic phase mechanisms in a rat model of CRPS. J. Neuroinflammation13, 14. 10.1186/s12974-015-0472-8
76
WildP.FarhanH.McEwanD. G.WagnerS.RogovV. V.BradyN. R.et al. (2011). Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science333, 228–233. 10.1126/science.1205405
77
WooS. R.FuertesM. B.CorralesL.SprangerS.FurdynaM. J.LeungM. Y.et al. (2014). STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity41, 830–842. 10.1016/j.immuni.2014.10.017
78
WuJ.DobbsN.YangK.YanN. (2020). Interferon-independent activities of mammalian STING mediate antiviral response and tumor immune evasion. Immunity53, 115–126.e115. 10.1016/j.immuni.2020.06.009
79
XiangH. C.LinL. X.HuX. F.ZhuH.LiH. P.ZhangR. Y.et al. (2019). AMPK activation attenuates inflammatory pain through inhibiting NF-κB activation and IL-1β expression. J. Neuroinflamm.16, 34. 10.1186/s12974-019-1411-x
80
XuM.FeiY.HeQ.FuJ.ZhuJ.TaoJ.et al. (2021). Electroacupuncture attenuates cancer-induced bone pain via NF-κB/CXCL12 signaling in midbrain periaqueductal gray. ACS Chem. Neurosci.12, 3323–3334. 10.1021/acschemneuro.1c00224
81
YuanJ.FeiY. (2021). Lidocaine activates autophagy of astrocytes and ameliorates chronic constriction injury-induced neuropathic pain. J. Biochem.170, 25–31. 10.1093/jb/mvaa136
82
YumS.LiM.FangY.ChenZ. J. (2021). TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections. Proc. Natl. Acad. Sci. U. S. A.118, e2100225. 10.1073/pnas.2100225118
83
ZhangW.LiG.LuoR.LeiJ.SongY.WangB.et al. (2022). Cytosolic escape of mitochondrial DNA triggers cGAS-STING-NLRP3 axis-dependent nucleus pulposus cell pyroptosis. Exp. Mol. Med.54, 129–142. 10.1038/s12276-022-00729-9
84
ZhangZ.ZhangX.ZhangY.LiJ.XingZ.ZhangY. (2020). Spinal circRNA-9119 suppresses nociception by mediating the miR-26a-TLR3 axis in a bone cancer pain mouse model. J. Mol. Neurosci.70, 9–18. 10.1007/s12031-019-01378-w
85
ZhouL.ZhangY. F.YangF. H.MaoH. Q.ChenZ.ZhangL. (2021). Mitochondrial DNA leakage induces odontoblast inflammation via the cGAS-STING pathway. Cell Commun. Signal.19, 58. 10.1186/s12964-021-00738-7
Summary
Keywords
cGAS-STING pathway, chronic pain, inflammation, autophagy, immunity, apoptosis
Citation
Wu J, Li X, Zhang X, Wang W and You X (2022) What role of the cGAS-STING pathway plays in chronic pain?. Front. Mol. Neurosci. 15:963206. doi: 10.3389/fnmol.2022.963206
Received
07 June 2022
Accepted
11 July 2022
Published
01 August 2022
Volume
15 - 2022
Edited by
Xin Zhang, Duke University, United States
Reviewed by
Xiaqing Ma, Medical School of Nantong University, China; Shunmei Lu, Wuxi People's Hospital Affiliated to Nanjing Medical University, China
Updates
Copyright
© 2022 Wu, Li, Zhang, Wang and You.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xingji You yoyo1976@shu.edu.cn
†These authors have contributed equally to this work
This article was submitted to Pain Mechanisms and Modulators, a section of the journal Frontiers in Molecular Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.